Altered B-cell, plasma cell and antibody immune profiles in blood of systemic mastocytosis.

B-lymphocyte immunoglobulin mast cell plasma cell systemic mastocytosis

Journal

The Journal of allergy and clinical immunology
ISSN: 1097-6825
Titre abrégé: J Allergy Clin Immunol
Pays: United States
ID NLM: 1275002

Informations de publication

Date de publication:
16 Oct 2024
Historique:
received: 30 04 2024
revised: 18 09 2024
accepted: 07 10 2024
medline: 19 10 2024
pubmed: 19 10 2024
entrez: 18 10 2024
Statut: aheadofprint

Résumé

Systemic mastocytosis (SM) is a heterogeneous disease characterised by an expansion of KIT-mutated constitutively activated mast cells (MC) which release MC mediators that might act on the tumour microenvironment including other immune cells. Here we investigated the blood distribution of B-cell, plasma cell (PC) and antibody-isotype compartments in SM. We used spectral flow cytometry and the EuroFlow Immunomonitoring panel and Lymphocyte Screening Tube to quantify B-cells, PC and their subsets in blood of 108 SM patients - 35 bone marrow mastocytosis (BMM), 64 indolent SM (ISM), 9 aggressive SM (ASM)- vs 117 age-matched healthy donors (HD) and paired bone marrow (BM) samples of 31 SM vs 17 controls, respectively. In parallel, immunoglobulin (Ig) M, IgD, IgG, IgA and IgE plasma levels of were measured. Compared to HD, SM patients showed an increased immature B-cell production in BM (P=0.003) associated with a greater release of pre-germinal center immature (P<0.001) and naive CD5 Our results reveal a significant dysregulation of the B-cell and PC compartments in blood of SM patients, consistent with distinctly altered antibody-isotype profiles in plasma of BMM vs ISM vs ASM patients.

Sections du résumé

BACKGROUND BACKGROUND
Systemic mastocytosis (SM) is a heterogeneous disease characterised by an expansion of KIT-mutated constitutively activated mast cells (MC) which release MC mediators that might act on the tumour microenvironment including other immune cells.
OBJECTIVE OBJECTIVE
Here we investigated the blood distribution of B-cell, plasma cell (PC) and antibody-isotype compartments in SM.
METHODS METHODS
We used spectral flow cytometry and the EuroFlow Immunomonitoring panel and Lymphocyte Screening Tube to quantify B-cells, PC and their subsets in blood of 108 SM patients - 35 bone marrow mastocytosis (BMM), 64 indolent SM (ISM), 9 aggressive SM (ASM)- vs 117 age-matched healthy donors (HD) and paired bone marrow (BM) samples of 31 SM vs 17 controls, respectively. In parallel, immunoglobulin (Ig) M, IgD, IgG, IgA and IgE plasma levels of were measured.
RESULTS RESULTS
Compared to HD, SM patients showed an increased immature B-cell production in BM (P=0.003) associated with a greater release of pre-germinal center immature (P<0.001) and naive CD5
CONCLUSION CONCLUSIONS
Our results reveal a significant dysregulation of the B-cell and PC compartments in blood of SM patients, consistent with distinctly altered antibody-isotype profiles in plasma of BMM vs ISM vs ASM patients.

Identifiants

DOI: 10.1016/j.jaci.2024.10.005 PMID: 39423877
pubmed: 39423877
pii: S0091-6749(24)01062-5
doi: 10.1016/j.jaci.2024.10.005
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2024. Published by Elsevier Inc.

Auteurs

Alba Pérez-Pons (A)

Cancer Research Center (IBMCC, USAL-CSIC), Department of Medicine and Cytometry Service (NUCLEUS), University of Salamanca (https://ror.org/02f40zc51), Salamanca, Spain; and Biomedical Research Institute of Salamanca (IBSAL), Salamanca, Spain; Biomedical Research Networking Center Consortium (CIBERONC; CB16/12/00400), Madrid, Spain; Spanish Network on Mastocytosis (REMA), Toledo and Salamanca, Spain.

Ana Henriques (A)

Spanish Network on Mastocytosis (REMA), Toledo and Salamanca, Spain; Instituto de Estudios de Mastocitosis de Castilla La Mancha (CLMast), Virgen del Valle Hospital, Toledo, Spain, Madrid, Spain.

Teresa Contreras Sanfeliciano (TC)

Department of Biochemistry, University Hospital of Salamanca, Salamanca, Spain.

María Jara-Acevedo (M)

Cancer Research Center (IBMCC, USAL-CSIC), Department of Medicine and Cytometry Service (NUCLEUS), University of Salamanca (https://ror.org/02f40zc51), Salamanca, Spain; and Biomedical Research Institute of Salamanca (IBSAL), Salamanca, Spain; Biomedical Research Networking Center Consortium (CIBERONC; CB16/12/00400), Madrid, Spain; Spanish Network on Mastocytosis (REMA), Toledo and Salamanca, Spain; Sequencing Service (NUCLEUS), University of Salamanca (https://ror.org/02f40zc51), Salamanca, Spain.

Paula Navarro-Navarro (P)

Cancer Research Center (IBMCC, USAL-CSIC), Department of Medicine and Cytometry Service (NUCLEUS), University of Salamanca (https://ror.org/02f40zc51), Salamanca, Spain; and Biomedical Research Institute of Salamanca (IBSAL), Salamanca, Spain; Biomedical Research Networking Center Consortium (CIBERONC; CB16/12/00400), Madrid, Spain; Spanish Network on Mastocytosis (REMA), Toledo and Salamanca, Spain; Sequencing Service (NUCLEUS), University of Salamanca (https://ror.org/02f40zc51), Salamanca, Spain.

Andrés C García-Montero (AC)

Cancer Research Center (IBMCC, USAL-CSIC), Department of Medicine and Cytometry Service (NUCLEUS), University of Salamanca (https://ror.org/02f40zc51), Salamanca, Spain; and Biomedical Research Institute of Salamanca (IBSAL), Salamanca, Spain; Biomedical Research Networking Center Consortium (CIBERONC; CB16/12/00400), Madrid, Spain; Spanish Network on Mastocytosis (REMA), Toledo and Salamanca, Spain.

Iván Álvarez-Twose (I)

Biomedical Research Networking Center Consortium (CIBERONC; CB16/12/00400), Madrid, Spain; Spanish Network on Mastocytosis (REMA), Toledo and Salamanca, Spain; Instituto de Estudios de Mastocitosis de Castilla La Mancha (CLMast), Virgen del Valle Hospital, Toledo, Spain, Madrid, Spain.

Quentin Lecrevisse (Q)

Cancer Research Center (IBMCC, USAL-CSIC), Department of Medicine and Cytometry Service (NUCLEUS), University of Salamanca (https://ror.org/02f40zc51), Salamanca, Spain; and Biomedical Research Institute of Salamanca (IBSAL), Salamanca, Spain; Biomedical Research Networking Center Consortium (CIBERONC; CB16/12/00400), Madrid, Spain.

Rafael Fluxa (R)

Cytognos SL, Salamanca, Spain.

Laura Sánchez-Muñoz (L)

Spanish Network on Mastocytosis (REMA), Toledo and Salamanca, Spain; Instituto de Estudios de Mastocitosis de Castilla La Mancha (CLMast), Virgen del Valle Hospital, Toledo, Spain, Madrid, Spain.

Carolina Caldas (C)

Cancer Research Center (IBMCC, USAL-CSIC), Department of Medicine and Cytometry Service (NUCLEUS), University of Salamanca (https://ror.org/02f40zc51), Salamanca, Spain; and Biomedical Research Institute of Salamanca (IBSAL), Salamanca, Spain; Spanish Network on Mastocytosis (REMA), Toledo and Salamanca, Spain.

Julio Pozo (J)

Cancer Research Center (IBMCC, USAL-CSIC), Department of Medicine and Cytometry Service (NUCLEUS), University of Salamanca (https://ror.org/02f40zc51), Salamanca, Spain; and Biomedical Research Institute of Salamanca (IBSAL), Salamanca, Spain.

Óscar González-López (Ó)

Cancer Research Center (IBMCC, USAL-CSIC), Department of Medicine and Cytometry Service (NUCLEUS), University of Salamanca (https://ror.org/02f40zc51), Salamanca, Spain; and Biomedical Research Institute of Salamanca (IBSAL), Salamanca, Spain; Spanish Network on Mastocytosis (REMA), Toledo and Salamanca, Spain.

Martín Pérez-Andrés (M)

Cancer Research Center (IBMCC, USAL-CSIC), Department of Medicine and Cytometry Service (NUCLEUS), University of Salamanca (https://ror.org/02f40zc51), Salamanca, Spain; and Biomedical Research Institute of Salamanca (IBSAL), Salamanca, Spain; Biomedical Research Networking Center Consortium (CIBERONC; CB16/12/00400), Madrid, Spain.

Andrea Mayado (A)

Cancer Research Center (IBMCC, USAL-CSIC), Department of Medicine and Cytometry Service (NUCLEUS), University of Salamanca (https://ror.org/02f40zc51), Salamanca, Spain; and Biomedical Research Institute of Salamanca (IBSAL), Salamanca, Spain; Biomedical Research Networking Center Consortium (CIBERONC; CB16/12/00400), Madrid, Spain; Spanish Network on Mastocytosis (REMA), Toledo and Salamanca, Spain.

Alberto Orfao (A)

Cancer Research Center (IBMCC, USAL-CSIC), Department of Medicine and Cytometry Service (NUCLEUS), University of Salamanca (https://ror.org/02f40zc51), Salamanca, Spain; and Biomedical Research Institute of Salamanca (IBSAL), Salamanca, Spain; Biomedical Research Networking Center Consortium (CIBERONC; CB16/12/00400), Madrid, Spain; Spanish Network on Mastocytosis (REMA), Toledo and Salamanca, Spain. Electronic address: orfao@usal.es.

Classifications MeSH